Chronic obstructive pulmonary disease (COPD) is associated with an increased cardiovascular risk, although the pathophysiological mechanisms responsible for this interdependence are not completely known. For instance, the increased sympathetic activity may be implied. The severity of COPD correlates with various arrhythmic manifestations such as atrial fibrillation, atrial flutter, and either sustained or nonsustained ventricular tachycardia. COPD and obstructive sleep apnea syndrome may increase the overall cardiovascular risk, especially in elderly patients. Additionally, electrolytic disorders may precipitate cardiac rhythm disturbances and thus cause important arrhythmic consequences such as ventricular fibrillation, as reported in our clinical case. We discuss here the possible treatment of this association of pathological conditions on the basis of a single case we have successfully treated, and provide a brief review of the available literature regarding cardiovascular comorbidities in COPD patients.

1.
Konecny T, Park JY, Somers KR, Konecny D, Orban M, Soucek F, Parker KO, Scanlon PD, Asirvatham SJ, Brady PA, Rihal CS: Relationship of COPD to atrial and ventricular arrhythmias. Am J Cardiol 2014; 114: 272–277.
2.
Matera MG, Rogliani P, Calzetta L, Cazzola M: Safety consideration with dual bronchodilator therapy in COPD: an update. Drug Saf 2016; 39: 501–508.
3.
Konecny T, Somers KR, Park JY, John A, Orban M, Doshi R, Scanlon PD, Asirvatham SJ, Rihal CS, Brady PA: Chronic obstructive pulmonary disease as a risk factor for ventricular arrhythmias independent of left ventricular function. Heart Rhythm 2017, Epub ahead of print
4.
Men XQ, Wang YK, Li J, Wei YQ, Xue C, Wang HQ: Nocturnal heart rhythm disorder in patients with obstructive sleep apnea syndrome (in Chinese). Zhonghua Yi Xue Za Zhi 2013; 93: 3655–3658.
5.
Parissis JT, Andreoli C, Kadoglou N, et al: Differences in clinical characteristics, management and short-term outcome among acute heart failure patients with COPD and those without this comorbidity. Clin Res Cardiol 2014; 103: 733–741.
6.
Anthonisen NR: The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142: 233–239.
7.
Sin DD: Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514–1519.
8.
Maclay JD: Vascular dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 513–520.
9.
Wedzicha JA: Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med 2016; 374: 2222–2234.
10.
Ficker JH: Role of dual bronchodilators in COPD: a review of the current evidence for indacaterol/glycopyrronium. Pulm Pharmacol Ther 2017; 45: 19–33.
11.
Bateman ED: Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013; 42: 1484–1494.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.